Proportion of cancers that show PD-L1 expression on the malignant cells11
| Cancer type | Proportion showing PD-L1 expression |
| Non-small cell carcinoma | 20%–30% (show expression in >50% cells) |
| Malignant melanoma | 24%–49% |
| Ovarian carcinoma | 70% |
| Breast carcinoma | 20% (of ‘triple negative’ tumours) |
| Colorectal carcinoma | 5% (associated with MMR deficiency) |
| Cholangiocarcinoma | 11%–30% |
| Pancreatic carcinoma | Rare |
| Head and neck carcinoma | 15%–20% |
| Urothelial carcinoma | 4% (but higher in TILs) |
| B cell lymphomas and Hodgkin’s disease | Common |
MMR, DNA mismatch repair enzyme;PD-L1, programmed death-ligand 1; TILs, tumour-infiltrating lymphocytes; triple negative, oestrogen receptor, progesterone receptor and HER-2 negative.